Reported total income of $4.7 million and $20.december 31 6 million for the three months and yr ended, 2013. Net reduction per share was $0.04 and $0.16 for the same periods. Ended the quarter with $69.1 million in cash and investments and no personal debt. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, ‘The October approval and subsequent first quarter release of OTREXUP to rheumatologists and dermatologists capped a remarkably successful season for our Company and our shareholders.’ He continued, ‘Our long-term eyesight of transforming Antares Pharma from a licensing Firm to a self-marketing, income generating specialty pharmaceutical Firm is now a reality. We are very happy to survey that early opinions from rheumatologists on the OTREXUP release is usually positive and we understand LEO Pharma is making good improvement with dermatologists on the usage of OTREXUP in psoriasis patients.The reason being testosterone binds to androgen receptors on the prostate malignancy cells and causes changes within the cells that result in faster development of the cancer. Bicalutamide works by stopping testosterone from binding to the androgen receptors on the prostate cancers cells. It starves prostate malignancy cells of testosterone therefore, which prevents them growing. Eventually the prostate tumour will shrink. Warning! : Your doctor might want you to have regular blood exams to monitor your liver function when you are taking this medicine. If this medicine is being taken by you in conjunction with a gonadorelin analogue your doctor may choose to monitor your blood sugar, should you have diabetes particularly.